The Effect of High-Fat Diet-Induced Pathophysiological Changes in the Gut on Obesity: What Should be the Ideal Treatment?

Chooi Y Lee, Chooi Y Lee

Abstract

Obesity is a metabolic disorder and fundamental cause of other fatal diseases including atherosclerosis and cancer. One of the main factor that contributes to the development of obesity is high-fat (HF) consumption. Lipid ingestion will initiate from the gut feedback mechanisms to regulate glucose and lipid metabolisms. But these lipid-sensing pathways are impaired in HF-induced insulin resistance, resulting in hyperglycemia. Besides that, duodenal lipid activates mucosal mast cells, leading to the disruption of the intestinal tight junction. Lipopolysaccharide that is co-transited with dietary fat postprandially, promotes the release of cytokines and the development of metabolic syndrome. HF-diet also alters microbiota composition and enhances fat storage. Although gut is protected by immune system and contains high level of antioxidants, obesity developed presumably when this protective mechanism is compromised by the presence of excessive fat. Several therapeutic approaches targeting different pathways have been proposed. There may be no one single most effective treatment, but all aimed to prevent obesity. This review will elaborate on the physiological and molecular changes in the gut that lead to obesity, and will provide a summary of potential treatments to manage these pathophysiological changes.

Figures

Figure 1
Figure 1
A multipronged mechanism that contributes to obesity development. (1) Luminal lipid activates gut lipid-sensing mechanisms to lower hepatic glucose production and maintain glucose homeostasis. These signaling pathways are suppressed by high-fat (HF) diet. (2) Interaction between microbiota and HF leads to the excessive release of adipocytokines, consequently obesity development. (3) As HF-diet increases 11β-HSD1 expression in the adipose tissues, which in turn promotes visceral obesity, it is likely that 11β-HSD1 enhances the release of adipocytokines, resulting in an effect similar to that observed between HF and microbiota. 11β-HSD1, 11β-hydroxysteroid dehydrogenase-1.

References

    1. McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29:29–48.
    1. Nguyen XT, Lane J, Smith BR, et al. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg. 2009;13:1205–1212.
    1. Ogden CL, Flegal KM, Carroll MD, et al. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288:1728–1732.
    1. Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance – a mini-review. Gerontology. 2009;55:379–386.
    1. Spagnuolo MI, Cicalese MP, Caiazzo MA, et al. Relationship between severe obesity and gut inflammation in children: what's next. Ital J Pediatr. 2010;36:66–71.
    1. Duparc T, Naslain D, Colom A, et al. Jejunum inflammation in obese and diabetic mice impairs enteric glucose detection and modifies nitric oxide release in the hypothalamus. Antioxid Redox Signal. 2011;14:415–423.
    1. Moran TH, Kinzig KP. Gastrointestinal satiety signals II. Cholecystokinin. Am J Physiol Gastrointest Liver Physiol. 2004;286:G183–G188.
    1. Wank S.Cholecystokinin receptors Am J Physiol 1995269Gastrointest Liver Physiol 32G628–G646.
    1. Cheung GWC, Kokorovic A, Lam CKL, et al. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab. 2009;10:99–109.
    1. Schwartz GJ, Fu J, Astarita G, et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab. 2008;8:281–288.
    1. Fu J, DiPatrizio NV, Guijarro A, et al. Sympathetic activity controls fat-induced oleoylethanolamide signaling in small intestine. J Neurosci. 2011;31:5730–5736.
    1. Wang PYT, Caspi L, Lam CKL, et al. Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature. 2008;452:1012–1016.
    1. Yen CLE, Cheong ML, Grueter C, et al. Deficiency of the intestinal enzyme acyl CoA: monoacylglycerol acyltransferease-2 protects mice from metabolic disorders induced by high-fat feeding. Nat Med. 2009;15:442–446.
    1. Obici S, Feng Z, Arduini A, et al. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med. 2003;9:756–761.
    1. Gillum MP, Zhang D, Zhang X, et al. N-acylphosphatidylethanolamine, a gut-derived circulating factor induced by fat ingestion, inhibits food intake. Cell. 2008;135:813–824.
    1. Diep TA, Madsen AN, Holst B, et al. Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor. FASEB J. 2011;25:765–774.
    1. Yen CE, Farese RV., Jr MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine. J Biol Chem. 2003;278:18532–18537.
    1. Srigiridhar K, Nair KM. Supplementation with alpha-tocopherol or a combination of alpha-tocopherol and ascorbic acid protects the gastrointestinal tract of iron-deficient rats against iron-induced oxidative damage during iron repletion. Br J Nutr. 2000;84:165–173.
    1. Brown ED, Morris VC, Rhodes DG, et al. Urinary malondialdehyde equivalents during ingestion of meat cooked at high or low temperatures. Lipids. 1995;30:1053–1056.
    1. Aw TY. Determinants of intestinal detoxication of lipid hydroperoxides. Free Radic Res. 1998;1925:637–646.
    1. Gopaul NK, Zacharowski K, Halliwell B, et al. Evaluation of the postprandial effect of a fast-food meal on human plasma F2-isoprostane and lipid peroxide levels. Free Radic Biol Med. 2000;28:806–814.
    1. Kanner J, Lapidot T. The stomach as a bioreactor: dietary lipid peroxidation in the gastric fluid and the effects of plant-derived antioxidants. Free Radic Biol Med. 2001;31:1388–1395.
    1. Halliwell B, Zhao K, Whiteman ML. The gastrointestinal tract: a major site of antioxidant action. Free Radic Res. 2000;33:819–830.
    1. Zhao K, Whiteman M, Spencer J, et al. DNA damage by nitrite and peroxynitrite: protection by dietary phenols. Methods Enzymol. 2001;335:296–307.
    1. Long LH, Lan ANB, Hsuan FTY, et al. Generation of hydrogen peroxide by ‘antioxidant' beverages and the effect of milk addition: is cocoa the best beverages. Free Radic Res. 1999;31:67–71.
    1. Long LH, Halliwell B. Coffee drinking increases levels of urinary hydrogen peroxide detected in healthy human subjects. Free Radic Res. 2000;32:463–467.
    1. Hiramoto K, Li X, Makimoto M. Identification of hydroxy-hydroquinone in coffee as a generator of reactive oxygen species that break DNA single strands. Mutat Res. 2001;419:43–51.
    1. Chamulitrat W. Activation of the superoxide-generating NADPH oxidase of intestinal lymphocytes produces highly reactive free radicals from sulfite. Free Radic Biol Med. 1999;27:411–421.
    1. Fujiyama Y, Hokari R, Miura S, et al. Butter feeding enhances TNF-α production from macrophages and lymphocyte adherence in murine small intestinal microvessels. J Gastroenterol Hepatol. 2007;22:1838–1845.
    1. Hara Y, Miura S, Komoto S, et al. Exposure to fatty acids modulates interferon production by intraepithelial lymphocytes. Immunol Lett. 2003;86:139–148.
    1. Yoshida H, Miura S, Kishikawa H, et al. Fatty acids enhance GRO/CINC-1 and interleukin-6 production in rat intestinal epithelial cells. J Nutr. 2001;131:2943–2950.
    1. Ji Y, Sakata Y, Tso P. Nutrient-induced inflammation in the intestine. Curr Opin Clin Nutr Metab Care. 2011;14:315–321.
    1. Scudamore CL, Jepson MA, Hirst BH, et al. The rat mucosal mast cell chymase, RMCP-II, alters epithelial cell monolayer permeability in association with altered distribution of the tight junction proteins ZO-1 and occluding. Eur J Cell Biol. 1998;75:321–330.
    1. Patrick MK, Dunn IJ, Buret A, et al. Mast cell protease release and mucosal ultrastructure during intestinal anaphylaxis in the rat. Gastroenterology. 1988;94:1–9.
    1. de La Serre CB, Ellis CL, Lee J, et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299:G440–G448.
    1. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007;86:1286–1292.
    1. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772.
    1. Goldberg RF, Austen WG, Jr, Zhang X, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci USA. 2008;105:3551–3556.
    1. Lu Y, Yeh W, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–151.
    1. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015–3025.
    1. Ding S, Chi MM, Scull BP, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One. 2010;5:e12191.
    1. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718–15723.
    1. Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007;104:979–984.
    1. Samuel BS, Shaito A, Motoike T, et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled reeptor, Gpr41. Proc Natl Acad Sci USA. 2008;105:16767–16772.
    1. Duca FA, Covasa M. Current and emerging concepts on the role of peripheral signals in the control of food intake and development of obesity. Br J Nutr. 2012;108:778–793.
    1. Liou AP, Lu X, Sei Y, et al. The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology. 2011;140:903–912.
    1. Tanaka T, Katsuma S, Adachi T, et al. Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:523–527.
    1. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–231.
    1. Serino M, Luche E, Gres S, et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut. 2012;61:543–553.
    1. Tehrani AB, Nezami BG, Gewirtz A, et al. Obesity and its associated disease: a role for microbiota. Neurogastroenterol Motil. 2012;24:305–311.
    1. Raikhlin N, Kvetnoy I. The synthesis of melatonin in the enterochromaffin cells. Archs Path. 1976;38:21–25.
    1. Huether G. The contribution of extrapineal sites of melatonin synthesis to circulating melatonin levels in higher vertebrates. Experientia. 1993;49:665–670.
    1. Zavodnik IB, Domanski AV, Lapshina EA, et al. Melatonin directly scavenges free radicals generated in red blood cells and a cell-free system: chemiluminescence measurements and theoretical calculations. Life Sci. 2006;79:391–400.
    1. Anisimov VN, Popovich IG, Zabezhinski MA, et al. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta. 2006;1757:573–589.
    1. Chen C, Fichna J, Bashashati M, et al. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol. 2011;17:3888–3898.
    1. Sjoblom M, Flemstrom G. Central nervous α1-adrenoceptor stimulation induces duodenal luminal release of melatonin. J Pineal Res. 2004;36:103–108.
    1. Larson GM, Jedstedt G, Nylander O, et al. Intracerebral adrenoceptor agonists influence rat duodenal mucosal bicarbonate secretion. Am J Physiol Gastrointest Liver Physiol. 1996;271:G831–G840.
    1. Sjoblom M, Jedstedt G, Flemstrom G. Peripheral melatonin mediates neural stimulation of duodenal mucosal bicarbonate secretion. J Clin Invest. 2001;108:625–633.
    1. Ercan F, Cetinel S, Contuk G, et al. Role of melatonin in reducing water avoidance stress-induced degeneration of the gastrointestinal mucosa. J Pineal Res. 2004;37:113–121.
    1. Khan R, Daya S, Potgieter B. Evidence for a modulation of the stress response by the pineal gland. Experientia. 1990;46:860–862.
    1. Canpolat S, Aydin M, Yasar A, et al. Effects of pinealectomy and exogenous melatonin on immunohistochemical ghrelin staining of arcuate nucleus and serum ghrelin levels in the rat. Neurosci Lett. 2006;410:132–136.
    1. Watanabe S, Yamaguchi M, Sobue T, et al. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako) J Nutr. 1998;128:1710–1715.
    1. Garsetti M, Pellegrini N, Baggio C, et al. Antioxidant activity in human faeces. J Nutr. 2000;84:705–710.
    1. Gee JM, Johnson IT. Polyphenolic compounds: interactions with the gut and implications for human health. Curr Med Chem. 2001;8:1245–1255.
    1. Asfar S, Abdeen S, Dashti H, et al. Effect of green tea in the prevention and reversal of fasting-induced intestinal mucosal damage. Nutrition. 2003;19:536–540.
    1. Bokkenheuser VD, Shackleton CHL, Winter J. Hydrolysis of dietary flavoniod glycosides by strains of intestinal Bacteroides from humans. Biochem J. 1987;248:953–956.
    1. McLean JA, Karadas F, Surai PF, et al. Lipid-soluble and water-soluble antioxidant activities of the avian intestinal mucosa at different sites along the intestinal tract. Comp Biochem Physiol Part B. 2005;141:366–372.
    1. Halliwell B, Rafter J, Jenner A. Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not. Am J Clin Nutr. 2005;81 (Suppl:268S–276SS.
    1. Ventura MT, Polimeno L, Amoruso AC, et al. Intestinal permeability in patients with adverse reactions to food. Dig Liver Dis. 2006;38:732–736.
    1. Watson AJ, Duckworth CA, Guan Y, et al. Mechanisms of epithelial cell shedding in the Mammalian intestine and maintenance of barrier function. Ann N Y Acad Sci. 2009;1165:135–142.
    1. Delzenne NM, Neyrinck AM, Cani PD. Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndrome. Microbial Cell Factories. 2011;10 (Suppl 1:S10.
    1. Mennigen R, Bruewer M. Effect of probiotics on intestinal barrier function. Ann N Y Acad Sci. 2009;1165:183–189.
    1. Resta-Lenert SC, Barrett KE. Modulation of intestinal barrier properties by probiotics: role in reversing colitis. Ann N Y Acad Sci. 2009;1165:175–182.
    1. Ukena SN, Singh A, Dringenberg U, et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS One. 2007;2:e1308.
    1. Murphy EF, Cotter PD, Hogan A, et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut. 62:220–226.
    1. Parnell JA, Reimer RA. Prebiotic fibres dose-dependently increase satiety hormones and alter Bacteroidetes and Firmicutes in lean and obese JCR:LA-cp rats. Br J Nutr. 2012;107:601–613.
    1. Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilisation of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15:940–945.
    1. Wang Z, Xiao G, Yao Y, et al. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma. 2006;61:650–657.
    1. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–2383.
    1. Cani PD, Possemiers S, de Wiele T Van, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091–1103.
    1. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–1481.
    1. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121:2126–2132.
    1. Hyatt T, Chen R, Wang X, et al. Effect of diabetes on enzymes involved in rat hepatic corticosterone production. J Diabetes. 2010;2:275–281.
    1. Matsuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–2170.
    1. Sahni-Arya B, Flynn MJ, Bergeron L, et al. Cofactor-specific modulation of 11β-hydroxysteroid dehydrogenase 1 inhibitor potency. Biochim Biophys Acta. 2007;1774:1184–1191.
    1. Bader T, Zoumakis E, Friedberg M, et al. Human adipose tissue under in vitro inhibition of 11β-hydroxysteroid dehydrogenase type 1: differentiation and metabolism changes. Horm Metab Res. 2002;34:752–757.
    1. McCormick KL, Wang X, Mick GJ. Evidence that the 11β-Hydroxysteroid dehydrogenase (11β-HSD1) is regulated by pentose pathway flux. J Biol Chem. 2006;281:341–347.
    1. Jurgonski A, Juskiewicz J, Zdunczyk Z, et al. Caffeoylquinic acid-rich extract from chicory seeds improves glycemia, atherogenic index, and antioxidant status in rats. Nutrition. 2012;28:300–306.
    1. Pozuelo MJ, Agis-Torres A, Hervert-Hernandez D, et al. Grape antioxidant dietary fiber stimulates Lactobacillus growth in rat cecum. J Food Sci. 2012;77:H59–H62.
    1. Anh Dao T, Waget A, Klopp P, et al. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS ONE. 2011;6:e20700.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa